DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2266535/sarepta-therapeutics-srpt-q1-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2266535 May 01, 2024 - Although the revenue and EPS for Sarepta Therapeutics (SRPT) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. 0

https://www.zacks.com/stock/news/2227400/henry-schein-hsic-set-to-post-q4-earnings-what-awaits?cid=CS-ZC-FT-analyst_blog|earnings_preview-2227400 Feb 16, 2024 - Henry Schein's (HSIC) fourth-quarter 2023 results are likely to reflect the resiliency of the dental and medical markets amid macroeconomic challenges. 0

https://www.zacks.com/stock/news/2227548/corcept-cort-q4-earnings-beat-estimates-korlym-sales-grow?cid=CS-ZC-FT-analyst_blog|earnings_article-2227548 Feb 16, 2024 - Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024. 0

https://www.zacks.com/stock/news/2229472/sarepta-srpt-to-report-q4-earnings-will-it-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2229472 Feb 21, 2024 - Investors' focus will likely be on Sarepta's (SRPT) product sales of its recently-approved DMD gene therapy when it reports fourth-quarter earnings. 0

https://www.fool.com/earnings/call-transcripts/2024/02/29/sarepta-therapeutics-srpt-q4-2023-earnings-call-tr/?source=iedfolrf0000001 Feb 28, 2024 - SRPT earnings call for the period ending December 31, 2023. 0

https://www.zacks.com/stock/news/2236810/regenxbio-rgnx-soars-15-on-interim-data-from-dmd-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2236810 Mar 06, 2024 - Data from an early-stage study shows that treatment with REGENXBIO's (RGNX) investigational Duchenne therapy RGX-202 demonstrates early evidence of strength and motor function improvement. 0

https://www.zacks.com/stock/news/2260559/gsk-gears-up-for-q1-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_article-2260559 Apr 23, 2024 - We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance. 0

https://www.zacks.com/stock/news/2264268/what-s-in-store-for-adma-biologics-adma-in-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2264268 Apr 29, 2024 - On ADMA Biologics' (ADMA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB. 0

https://www.zacks.com/stock/news/2266374/sarepta-therapeutics-srpt-q1-earnings-and-revenues-beat-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2266374 May 01, 2024 - Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 763.64% and 10.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.fool.com/earnings/call-transcripts/2024/05/01/sarepta-therapeutics-srpt-q1-2024-earnings-call-tr/?source=iedfolrf0000001 May 01, 2024 - SRPT earnings call for the period ending March 31, 2024. 0